Literature DB >> 17149740

Hypomyelinating leukoencephalopathy with paroxysmal tonic upgaze and absence of psychomotor development.

Lubov Blumkin1, Dorit Lev, Nathan Watemberg, Tally Lerman-Sagie.   

Abstract

Hypomyelinating leukoencephalopathies are characterized by a substantial and permanent deficit in myelin deposition in the brain. Although our knowledge and understanding of the etiology of white matter diseases has progressively increased, many cases with this disorder remain undiagnosed, despite extensive evaluations. Recently, new disease entities have been defined by combining magnetic resonance imaging pattern recognition and clinical features. We describe a 1-year-old Ashkenazi Jewish girl with a hypomyelinating leukoencephalopathy, who presented in the neonatal period with episodes of sustained paroxysmal tonic upward gaze, roving eye movements, pendular nystagmus, and severe hypotonia, with the later appearance of pyramidal and extrapyramidal signs and no development. In addition, she has dysmorphic signs. This clinical picture is not consistent with any of the previously described hypomyelinating leukoencephalopathies and may represent a new entity. (c) 2006 Movement Disorder Society.

Entities:  

Mesh:

Year:  2007        PMID: 17149740     DOI: 10.1002/mds.21277

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  2 in total

Review 1.  Paroxysmal tonic upgaze accompanied by occipital discharge on electroencephalography: a case report and literature review.

Authors:  Yan-Feng Zhang; Yi-Zhu Wang; Xiao-Sheng Hao; Hong-Bo Zhang; Jiang-Tao Wang; Jian-Min Liang
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

2.  A new entity of hypomyelination with atrophy of basal ganglia and cerebellum-like syndrome with bilateral developmental cataract.

Authors:  Linda Maria Genoveva De Piedade Sequeira; Gowri Poigaialwar; Shashikant Shetty; P Sundaresan; P Vijayalakshmi
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.